^
Association details:
| Biomarker: | MYC overexpression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | narazaciclib (HX301) (CDK4 inhibitor, CDK6 inhibitor, CSF-1R inhibitor, ARK5 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
497 / 28 - HX301, a first-in-class ARK5i, demonstrates antitumor activity in preclinical HCC models with high ARK5/Myc expression
Published date:
03/15/2023
Excerpt:
Subcutaneous tumor responses to HX301 were calculated by tumor growth inhibition (TGI)...HCC PDX models LI1035, LI6610 both had high expression of ARK5 and Myc genes, whereas LI6650 had lower expression level of Myc than LI1035 and LI6610….The TGI for LI1035 and LI6610 was 64% (P = 0.0293) and 62% (P = 0.0257) respectively...Our preliminary results demonstrate that HX301 had strong antitumor activity in HCC PDX models expressing both ARK5 and c-Myc. HX301 has the potential to be a first-in-class ARK5i candidate for the treatment of advanced HCC with high expression of c-Myc, warranting further clinical investigation.
